Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000487
First received: October 27, 1999
Last updated: June 23, 2005
Last verified: March 2005
  Purpose

To determine for a group of men at high risk of death from coronary heart disease whether a special intervention program to lower serum cholesterol, reduce blood pressure, and eliminate cigarette smoking would result in a significant reduction in mortality from coronary heart disease.


Condition Intervention Phase
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Drug: antihypertensive agents
Behavioral: smoking cessation
Behavioral: diet, fat-restricted
Drug: diuretics
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: June 1972
Estimated Study Completion Date: July 1998
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   35 Years to 57 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Men, ages 35-57. One or more of three risk factors--hypertension, hypercholesterolemia, and cigarette smoking.

Free from coronary heart disease.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000487

Sponsors and Collaborators
Investigators
Investigator: Marcus Kjelsberg University of Minnesota - Clinical and Translational Science Institute
  More Information

Publications:
Stamler J, Paul O, Berkson DM, et al: The New National Cooperative Multiple Risk Factor Intervention Trial (Heart Attack Prevention Program). Chicago Medicine, 76:1047-1048, 1973.
Multiple Risk Factor Intervention Trial Group: Multiple Risk Factor Intervention Trial. Proceedings of the Nutrition Behavioral Research Conference. NHLBI, NIH, DHEW Publication No. (NIH) 76-978, p. ll, l975.
Multiple Risk Factor Intervention Trial Group: Public Annual Report, Multiple Risk Factor Intervention Trial, June 30, l974 to July l, l975. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, DHEW Publication No. (NIH) 76-l000, August, l975.
Multiple Risk Factor Intervention Trial Group: Smoking Cessation Activities in the Multiple Risk Factor Intervention Trial: A Preliminary Report.J. Steinfeld et al (Eds). Smoking & Health: Proceedings of the Third World Conference on Smoking and Health, June 2-5, l975, II Health Consequences, Education, Cessation Activities, and Social Action, U.S. Government Printing Office, Washington, D.C., l976, 6l3-6l7.
Multiple Risk Factor Intervention Trial Group: Public Annual Report, Multiple Risk Factor Intervention Trial, June 30, l975 to July l, l976. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, DHEW Publication No. (NIH) 77-l2ll, August, l976.
Ockene J: Multiple Risk Factor Intervention Trial: Smoking Cessation Procedures and Cessation Patterns for a Large Cohort of MRFIT Participants. In Schwartz J (Ed): Progress in Smoking Cessation, American Cancer Society, New York, p. 183-198, 1979.
Hymowitz N: The Multiple Risk Factor Intervention Trial: A Four Year Evaluation. Int J Ment Health, 11:44-67, 1982.
Shekelle RB, Caggiula AW, Grimm RH: Diuretic Treatment of Hypertension and Changes in Plasma Lipids Over Six Years in the Multiple Risk Factor Intervention Trial. In Hegyeli RJ (Ed): Atherosclerosis Review. New York, Raven, p. 113-127, 1984.
Kuller L: Risk Factor Reduction in CHD. Modern Concepts of Cardiovascular Disease, 53:7-11, 1984.
Shekelle R: Diuretic Treatment of Hypertension and Changes in Plasma Lipids Over Six Years in the Multiple Risk Factor Intervention Trial. In Paoletti R, et al (Eds): Endpoints for Cardiovascular Drug Studies. New York, Raven, p. 216, 1984.
Leon AS, Connett J, Jacobs DR, et al: Relation of Leisure Time Physical Activity to Mortality in the Multiple Risk Factor Intervention Trial. Circulation, 70 (Suppl 2) II-644, 1984.
Stamler J: The Multiple Risk Factor Intervention Trial (MRFIT). In Hoffman H (Ed): Primary and Secondary Prevention of Coronary Heart Disease. Berlin, Heidelberg, Springer-Verlag, 8-33, 1985.
Sherwin R: Diuretics, Serum Potassium and Mortality in the Multiple Risk Factor Intervention Trial (MRFIT). In Whelton T, et al (Eds): Potassium in Cardiovascular and Renal Medicine, New York, Marcelle Decker, 293-303, 1986.
Ockene JK, Hulley SB, Gerace TA: Smoking Behavior Change Patterns in the Multiple Risk Factor Intervention Trials (MRFIT) and Their Relationship to Mortality from Coronary Heart Disease (CHD). Proceedings of the Fifth World Conference on Smoking and Health, Winnipeg, Canada, 1983 403-414, (Jan 1986).
Neaton JD, Kuller L, Stamler J, Wentworth D. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Ed. New York: Raven Press,Ltd., 1995:127-144.
Dietary and Nutritional Methods and Findings: the Multiple Risk Factor Intervention Trial (MRFIT). Stamler J, Caggiula AW, Cutler JA, et al (Eds): Supplement to American Journal of Clinical Nutrition. 65(1), January 1997.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000487     History of Changes
Other Study ID Numbers: 6
Study First Received: October 27, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Coronary Disease
Heart Diseases
Ischemia
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Pathologic Processes
Antihypertensive Agents
Diuretics
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Natriuretic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 20, 2014